ArticleJournal of managed care & specialty pharmacy2019

The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Le H Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.